December 12, 2008 - 4:32 p.m.
Gilead Sciences Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
Printer Friendly Version 
December 03, 2008 - 5:02 p.m.
Data Demonstrating Significant Efficacy of Viread(R) in Treating Chronic Hepatitis B Published in New England Journal of Medicine
Printer Friendly Version 
November 25, 2008 - 4:18 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
November 14, 2008 - 4:31 p.m.
Gilead Sciences Announces Notification of ANDA Filing for Truvada
Printer Friendly Version 
November 05, 2008 - 4:18 p.m.
Gilead Sciences to Present at Three Upcoming Investor Conferences
Printer Friendly Version 
November 01, 2008 - 11:02 a.m.
Gilead Announces Two-Year Data from Pivotal Phase III Studies Evaluating Viread(R) for Chronic Hepatitis B
Printer Friendly Version 
October 30, 2008 - 4:17 p.m.
Gilead Sciences to Present at the Oppenheimer 19th Annual Healthcare Conference on Tuesday, November 4
Printer Friendly Version 
October 28, 2008 - 12:02 p.m.
Gilead Announces Two-Year Clinical Data for Letairis(R) (ambrisentan) for the Treatment of Pulmonary Arterial Hypertension (WHO Group 1)
Printer Friendly Version 
October 23, 2008 - 4:17 p.m.
Gilead Signs Agreement with EFI to Acquire Building and Associated Land Bordering Gilead's Foster City Campus
Printer Friendly Version 
October 16, 2008 - 4:06 p.m.
Gilead Sciences Announces Third Quarter 2008 Financial Results
Printer Friendly Version 
October 09, 2008 - 4:17 p.m.
Gilead Sciences to Release Third Quarter 2008 Financial Results on Thursday, October 16, 2008
Printer Friendly Version 
September 16, 2008 - 6:56 p.m.
Gilead Receives Complete Response Letter from U.S. Food and Drug Administration for Aztreonam Lysine for Inhalation, an Investigational Treatment for Cystic Fibrosis
Printer Friendly Version 
September 11, 2008 - 4:53 p.m.
Seigo Izumo, MD Joins Gilead as Senior Vice President, Cardiovascular Therapeutics
Printer Friendly Version 
September 10, 2008 - 5:31 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
August 27, 2008 - 4:17 p.m.
Gilead Sciences to Present at the Thomas Weisel Partners Healthcare Conference on Wednesday, September 3
Printer Friendly Version 
August 11, 2008 - 6:10 p.m.
U.S. Food and Drug Administration Approves Viread(R) for Chronic Hepatitis B in Adults
Printer Friendly Version 
August 01, 2008 - 8:33 a.m.
Gilead Sciences and Merck & Co., Inc. Enter Into an Agreement to Register and Distribute HIV Medication Atripla(R) (Efavirenz 600 mg/ Emtricitabine 200 mg/ Tenofovir Disoproxil Fumarate 300 mg) in Twelve Countries
Printer Friendly Version 
July 31, 2008 - 8:32 a.m.
Richard J. Whitley, MD Joins Gilead Sciences' Board of Directors
Printer Friendly Version 
July 22, 2008 - 4:17 p.m.
Gilead Initiates Phase III Clinical Trial of Elvitegravir, an Investigational Integrase Inhibitor for HIV
Printer Friendly Version 
July 17, 2008 - 4:07 p.m.
Gilead Sciences Announces Second Quarter 2008 Financial Results
Printer Friendly Version 
July 08, 2008 - 4:17 p.m.
Gilead Sciences to Release Second Quarter 2008 Financial Results on Thursday, July 17, 2008
Printer Friendly Version 
June 13, 2008 - 8:32 a.m.
Gilead Announces Interim 12-Month Phase III Study Results for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
Printer Friendly Version 
June 04, 2008 - 4:17 p.m.
Gilead Sciences to Present at the 29th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 11
Printer Friendly Version 
June 02, 2008 - 1:40 p.m.
U.S. Patent Office Confirms Second of Four Viread(R) Patents
Printer Friendly Version 
May 29, 2008 - 4:17 p.m.
Gilead and Navitas Announce Agreement for Cicletanine for the Treatment of Pulmonary Arterial Hypertension
Printer Friendly Version 
May 29, 2008 - 8:32 a.m.
Data from Pivotal Phase III Studies of Gilead's Letairis(R) (ambrisentan) for Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms Published in Circulation
Printer Friendly Version 
May 22, 2008 - 4:32 p.m.
Gilead Sciences' Chairman and Chief Executive Officer Establishes Rule 10b5-1 Stock Trading Plan
Printer Friendly Version 
May 20, 2008 - 5:06 p.m.
U.S. Patent Office Confirms First of Four Viread(R) Patents
Printer Friendly Version 
May 20, 2008 - 10:47 a.m.
Gilead Announces New Letairis(R) (Ambrisentan) Data for the Treatment of Patients With Pulmonary Arterial Hypertension (WHO Group 1) With WHO Functional Class II or III Symptoms
Printer Friendly Version 
May 14, 2008 - 4:17 p.m.
Gilead Sciences to Present at the 2008 Citi Investment Research Global Healthcare Conference on Wednesday, May 21
Printer Friendly Version 
May 13, 2008 - 5:19 p.m.
Gilead Sciences' Board Member Establishes Rule 10b5-1 Stock Trading Plan
Printer Friendly Version 
May 09, 2008 - 4:17 p.m.
Gilead Sciences to Present at the Bank of America 2008 Healthcare Conference on Tuesday, May 13
Printer Friendly Version 
May 07, 2008 - 4:16 p.m.
Gilead Appoints John C. Martin as Chairman of Board of Directors; Names John F. Milligan President
Printer Friendly Version 
May 01, 2008 - 4:07 p.m.
Gilead Initiates Letairis(R) (ambrisentan) Phase IV Program
Printer Friendly Version 
April 25, 2008 - 9:24 a.m.
European Commission Approves Viread(R) for Chronic Hepatitis B
Printer Friendly Version 
April 24, 2008 - 4:08 p.m.
Gilead Sciences to Present at the Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, April 30
Printer Friendly Version 
April 24, 2008 - 3:02 a.m.
Gilead Announces 72-Week Data From Two Pivotal Phase III Studies Evaluating Viread(R) for the Treatment of Chronic Hepatitis B
Printer Friendly Version 
April 21, 2008 - 8:33 a.m.
Robin L. Washington to Join Gilead as Senior Vice President and Chief Financial Officer
Printer Friendly Version 
April 16, 2008 - 4:07 p.m.
Gilead Sciences Announces First Quarter 2008 Financial Results
Printer Friendly Version 
April 09, 2008 - 4:16 p.m.
Gilead Sciences to Release First Quarter 2008 Financial Results on Wednesday, April 16, 2008
Printer Friendly Version 
March 19, 2008 - 4:04 p.m.
European CHMP Issues Positive Opinion for Viread(R) for the Treatment of Chronic Hepatitis B
Printer Friendly Version 
March 10, 2008 - 4:31 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
March 07, 2008 - 8:32 a.m.
Gilead Sciences Submits Marketing Authorisation Application for Aztreonam Lysine 75 mg Powder for Nebuliser Solution, a Potential New Treatment for Cystic Fibrosis, to European Medicines Agency
Printer Friendly Version 
March 06, 2008 - 4:32 p.m.
Gilead Appoints Dr. John J. Toole as Senior Vice President, Corporate Development
Printer Friendly Version 
February 29, 2008 - 6:43 p.m.
Gilead Announces $500 Million Accelerated Share Repurchase
Printer Friendly Version 
January 30, 2008 - 4:17 p.m.
Gilead Sciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Tuesday, February 5
Printer Friendly Version 
January 23, 2008 - 4:07 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2007 Financial Results
Printer Friendly Version 
January 21, 2008 - 11:02 a.m.
Gilead Announces Departure of Caroline Dorsa
Printer Friendly Version 
January 16, 2008 - 4:17 p.m.
Gilead Sciences to Release Fourth Quarter and Year End 2007 Financial Results on Wednesday, January 23, 2008
Printer Friendly Version 
January 03, 2008 - 4:17 p.m.
Gilead Sciences to Present at the 26th Annual JPMorgan Healthcare Conference on Monday, January 7
Printer Friendly Version 
NASDAQ (US Dollar)
$81.21
 Stock is Down 0.38 (0.47%)
Data as of 10/20/17 4:15 p.m. ET
Minimum 20 minute delay
Refresh Quote